Novartis: arthritis drug meets goal in late-stage trial
(CercleFinance.com) - Novartis said that its psoriasis drug Cosentyx has met the primary endpoint of a final stage trial for the treatment of patients with axial spondyloarthritis, showing a "significant and clinically meaningful" reduction in disease activity.
The ongoing Phase III trial, - which enrolled 555 male and female adult patients with active non-radiographic axial spondyloarthritis - met its primary endpoint at week 16, taking the treatment one step toward its final marketing approval.
There are approximately 1.7 million patients with non-radiographic axial spondyloarthritis in the EU and US.
The disease entails chronic inflammatory back pain and other symptoms such as nocturnal pain.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The ongoing Phase III trial, - which enrolled 555 male and female adult patients with active non-radiographic axial spondyloarthritis - met its primary endpoint at week 16, taking the treatment one step toward its final marketing approval.
There are approximately 1.7 million patients with non-radiographic axial spondyloarthritis in the EU and US.
The disease entails chronic inflammatory back pain and other symptoms such as nocturnal pain.
Copyright (c) 2019 CercleFinance.com. All rights reserved.